Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 3, 2006, Pages 119-127

  Hassan Alin, Mohammed ^a   Andersson, T ^b   Niazi, M ^a   Liljeblad, M ^a   Persson, B A ^a   Rohss K ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Esomeprazole; Helicobacter pylori eradication; Proton pump inhibitor; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 33644760216     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44119     Document Type: Article

References (13)

1. Äbelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L 2000 Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28: 966-972
2. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ 1993 Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521-530
3. Andersson T, Miners JO, Veronese ME, Birkett DJ 1994 Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37: 597-604
4. Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L 2000 Pharmacokinetics (PK) and effect on pentagastrin-stimulated peak acid output (PAO) of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). Gastroenterology 118: A1210 (abstract 5551)
5. Astra Hässle AB 1997 An interaction study between omeprazole, amoxicillin and clarithromycin. Study SH-OMH-0016: (Data on file)
6. Bottiger Y, Tybring G, Gotharson E, Bertilsson L 1997 Inhibition of the sulfoxidation of omeprazole by ketokonazole in poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 62: 384-391
7. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E 1999 Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 66: 265-274
8. Hardman JG, Limbird LE (eds) 1996 Goodman & Gillman's The Pharmacological Basis of Therapeutics (9th ed). McGraw-Hill, New York, 1715
9. Hassan-Alin M, Andersson T, Niazi M, Röhss K 2005 A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole, and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole in healthy subjects. Eur J Clin Pharmacol 60: 779-784
10. Jurima-Romet M, Crawford K, Cyr T, Inaba T 1994 Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azoli fungals. Drug Metab Dispos 22: 849-857
11. Lagerström PO, Persson BA 1984 Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 309: 347-356
12. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K 2000 Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14: 861-867
13. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D 1997 Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25: 623-630